Search research articles
Contact Us
Filters
Showing results (51-60 of 65) with videos related to
Page
of 7
Sort By:
Cancer Research
|
August 14, 2015
Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy
Russell Hughes, Bin-Zhi Qian, Charlotte Rowan, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 19, 2022
Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial
Solange Peters, Igor Letovanec, Murielle Mauer, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 19, 2018
Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study
Christos Chouaid, Sarah Danson, Stefan Andreas, et al.
Lung Cancer (Amsterdam, Netherlands)
|
July 3, 2018
Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS)
Stefan Andreas, Christos Chouaid, Sarah Danson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 21, 2021
Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE)
Simon J Crabb, Sarah Danson, James W F Catto, et al.
BMC Cancer
|
July 2, 2021
The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma
Oliver Coen, Pippa Corrie, Helen Marshall, et al.
The Lancet. Oncology
|
October 17, 2021
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial
Dean A Fennell, Sean Ewings, Christian Ottensmeier, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 28, 2024
A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma
Joseph J Sacco, Richard Jackson, Pippa Corrie, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 20, 2021
Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials
Solange Peters, Sarah Danson, Dunson Ejedepang, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 29, 2023
A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAF<sup>V600</sup> mutant advanced melanoma (INTERIM)
Alimu Dayimu, Avinash Gupta, Rubeta N Matin, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 65) with videos related to
Sort By:
Page
of 7
Cancer Research
|
August 14, 2015
Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy
Russell Hughes, Bin-Zhi Qian, Charlotte Rowan, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 19, 2022
Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial
Solange Peters, Igor Letovanec, Murielle Mauer, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 19, 2018
Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study
Christos Chouaid, Sarah Danson, Stefan Andreas, et al.
Lung Cancer (Amsterdam, Netherlands)
|
July 3, 2018
Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS)
Stefan Andreas, Christos Chouaid, Sarah Danson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 21, 2021
Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE)
Simon J Crabb, Sarah Danson, James W F Catto, et al.
BMC Cancer
|
July 2, 2021
The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma
Oliver Coen, Pippa Corrie, Helen Marshall, et al.
The Lancet. Oncology
|
October 17, 2021
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial
Dean A Fennell, Sean Ewings, Christian Ottensmeier, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 28, 2024
A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma
Joseph J Sacco, Richard Jackson, Pippa Corrie, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 20, 2021
Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials
Solange Peters, Sarah Danson, Dunson Ejedepang, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 29, 2023
A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAF<sup>V600</sup> mutant advanced melanoma (INTERIM)
Alimu Dayimu, Avinash Gupta, Rubeta N Matin, et al.
Page
of 7